FDA Fixes Earlier Notice on Generic Drug Approvals
Published Date: 6/16/2026
Notice
Summary
The FDA fixed a mistake about pulling approval for 11 drug applications. Masuu Global Solutions, representing Extrovis AG, asked to keep their drug approvals, so those stay active. This means no sudden changes or money impacts for them as of March 23, 2026.
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19704, Robotically-Assisted Surgical Devices-Premarket Submissions; Draft Guidance for Industry and Food and Drug Administration Staff; Availability
The FDA just dropped a draft guide for companies making robot-assisted surgical devices, showing how to get their products approved before selling. If you’re in the biz, now’s the time to check it out and send your feedback by November 24, 2026. This guide aims to make the approval process clearer and smoother, potentially saving time and money down the road.
2026-19655, Jeffrey Thies: Final Debarment Order
Jeffrey Thies is banned for 10 years from importing any drugs into the U.S. because he was convicted of trafficking fake drugs. He didn’t respond to the FDA’s notice, so the ban started on September 25, 2026. He can apply to end the ban anytime, but until then, no drug imports for him!
Previous / Next Documents
Previous: 2026-12042, Petition for Exemption; Summary of Petition Received; Amor Fati Industries Corp
Amor Fati Industries Corp asked the FAA to be excused from some aviation rules to help their business run smoother. This affects pilots and companies who follow these rules and could speed up certain operations without extra costs. The public can share their thoughts by July 6, 2026, so don’t miss your chance to weigh in!
Next: 2026-12045, EnergySolutions, LLC and Bridgepoint Group PLC; Consideration of Approval of Transfer of Licenses
EnergySolutions wants to hand over some important nuclear licenses to Bridgepoint Group, and the Nuclear Regulatory Commission is deciding if that’s okay. This affects both companies and anyone interested in nuclear safety, with a chance to comment or ask for a hearing by early to mid-July 2026. No big money changes are mentioned, but the process is official and open for public input.